Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 04, 2026, titled "Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Phase 3 Study of Masupirdine in Alzheimer's Disease Agitation at 50% study completers Study to Continue Unchanged".
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences announced that the Data Safety Monitoring Board (DSMB) has completed a positive safety review and interim analysis of its ongoing global Phase 3 study of Masupirdine for treating agitation in Alzheimer's Disease patients. The review was triggered at the 50% study completion milestone. The DSMB recommended that the study continue unchanged, with no safety concerns flagged and no modifications needed to the trial protocol. This is an important clinical milestone as it de-risks the safety profile of the lead drug candidate at the halfway point of the pivotal Phase 3 trial.
Positive news for shareholders as it removes a key safety overhang at the halfway mark of the Phase 3 trial, keeping Suven on track for potential future regulatory submission. However, this is an interim safety update, not an approval, so the stock may see only a modest reaction until efficacy data is available.